Needham Maintains Buy on Veradermics, Raises Price Target to $164
Veradermics, Incorporated
Veradermics, Incorporated MANE | 0.00 |
Needham analyst Serge Belanger maintains Veradermics (NYSE:
MANE) with a Buy and raises the price target from $136 to $164.
